Download PDF
Vet Comp Orthop Traumatol 1994; 07(01): 77-81
DOI: 10.1055/s-0038-1633046
Original Research
Schattauer GmbH

The Effects of Polysulfated Glycosaminoglycan (Adeqtiail®) on Activated Partial Thromboplastin Time, Prothrombin Time, Complete Blood Count, Biochemical Profile and Urinalysis in Cats

J. J. de Haan
1   From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
,
B. S. Beale
1   From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
,
R. M. Clemmons
1   From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
,
Laura Clark
1   From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Florida, USA
› Author Affiliations
Further Information

Publication History

Received for publication 26 July 1993

Publication Date:
06 February 2018 (online)

    Permissions and Reprints

Summary

The effects of a single intramuscular administration of polysulfated glycosaminoglycan (PSGAG, Adequan®a) on activated partial thromboplastin time (APTT), prothrombin time (PT), complete blood count (CBC), biochemical profile and urinalysis were determined in six adult cats. An injection of 5 mg/kg of PSGAG was given to three of the cats, and an injection of 25 mg/kg was given to the other three cats. Following a seven-day crossover interval, the doses were reversed. Serial blood and urine samples were collected over a 48-hour period after each injection. Administration of PSGAG resulted in a transient, dose-dependent increase of APTT and PT. Prolonged bleeding from the venipuncture sites in the 25 mg/kg group was observed. Some of the CBC, biochemical profile, and urinalysis values changed following treatment, but clinically significant adverse reactions were not noticed.

Polysulfated glycosaminoglycan (Adequan®) is a heparin analogue with chondroprotective and anticoagulant properties. A single intramuscular injection of 5 mg/kg and 25 mg/kg of polysulfated glycosaminoglycan in six healthy adult cats resulted in a transient, dose-dependent increase of activated partial thromboplastin time and prothrombin time. Minor changes were seen on complete blood count, biochemical profile and urinalysis.

Keywords

Adequan® - polysulfated glycosaminoglycan - feline - systemic effects
 

  • References

  • 1 Burkhardt D, Ghosh P. Laboratory evaluation of glycosaminoglycan polysulphate ester for chondroprotective activity: a review. Curr Ther Res 1986; 40: 1034-53.
    PubMedGoogle Scholar
  • 2 Hamm D, Goldman L, Jones EW. Polysul-fated glycosaminoglycan: a new intra-articular treatment for equine lameness. Vet Med/ SAC 1984; 79: 811-6.
    PubMedGoogle Scholar
  • 3 Glade MJ. Polysulfated glycosaminoglycan accelerates net synthesis of collagen and glycosaminoglycans by arthritic equine cartilage tissues and chondrocytes. Am J Vet Res 1990; 51: 779-85.
    PubMedGoogle Scholar
  • 4 Halverson PB, Cheung HS, Struve J, McCarty DJ. Suppression of active collagenase from calcified lapine synovium by Arteparon. J Rheumatol 1987; 14: 1013-6.
    PubMedGoogle Scholar
  • 5 Steinmeyer J, Burton-Wurster N, Lust G. Effects of three antiarthritic drugs on fibronectin and keratan sulfate synthesis by cultured canine articular cartilage chondrocytes. Am J Vet Res 1992; 53: 2077-83.
    PubMedGoogle Scholar
  • 6 Howell DS, Carreno MR, Pelletier JP, Muniz OE. Articular cartilage breakdown in a lapine model of osteoarthritis. Clin Orthop Rel Res 1986; 213: 69-76.
    PubMedGoogle Scholar
  • 7 Howell DS, Muniz OE, Carreno MR. Effect of glycosaminoglycan polysulfate ester on proteoglycan-degrading enzyme activity in an animal model of osteoarthritis. Adv Inflam Res 1986; 11: 197-206.
    PubMedGoogle Scholar
  • 8 Carreno MR, Muniz OE, Howell DS. The effect of glycosaminoglycan polysulfuric acid ester on articular cartilage in experimental osteoarthritis: effects on morphological variables of disease severity. J Rheumatol 1986; 13: 490-7.
    PubMedGoogle Scholar
  • 9 Golding J, Ghosh P. Drugs for osteoarthrosis II: the effects of a glycosaminoglycan polysulphate ester (Arteparon) on proteoglycan aggregation and loss from articular cartilage of immobilized rabbit knee joints. Curr Ther Res 1983; 34: 67-80.
    PubMedGoogle Scholar
  • 10 Vanharanta H. Glycosaminoglycan polysulphate treatment in experimental osteoarthritis in rabbits. Scand J Rheumatol 1983; 12: 225-30.
    CrossrefPubMedGoogle Scholar
  • 11 Altman RD, Dean DD, Muniz OE, Howell DS. Prophylactic treatment of canine osteo-arthritis with glycosaminoglycan polysulfuric acid ester. Arthritis Rheum 1989; 32: 759-66.
    CrossrefPubMedGoogle Scholar
  • 12 Altman RD, Dean DD, Muniz OE, Howell DS. Therapeutic treatment of canine osteo-arthritis with glycosaminoglycan polysulfuric acid ester. Arthritis Rheum 1989; 32: 1300-7.
    CrossrefPubMedGoogle Scholar
  • 13 Altman RD, Howell DS, Muniz OE, Dean DD. The effect of glycosaminoglycan poly-sulfuric acid ester on articular cartilage in experimental arthritis. J Rheumatol 1987; 14: 127-9.
    PubMedGoogle Scholar
  • 14 Altman RD, Muniz OE, Howell DS, Dean DD. Effect of therapeutic treatment with glycosaminoglycan polysulfuric acid ester on cartilage swelling properties and proteinases in osteoarthritis. Abstract. 34th Annual Meeting, Orthop Res Soc 1988: 490.
    PubMedGoogle Scholar
  • 15 Hannan N, Ghosh P, Bellenger C, Taylor T. Systemic administration of glycosaminoglycan polysulphate (Arteparon) provides partial protection of articular cartilage from damage produced by meniscectomy in the canine. J Orthop Res 1987; 5: 47-59.
    CrossrefPubMedGoogle Scholar
  • 16 Ueno R. Results of intramuscular administration of glycosaminoglycan polysulfate (GAGPS) in experimental arthrosis of the knee joint of dogs. Z Orthop Grenzgeb 1976; 114: 108.
    PubMedGoogle Scholar
  • 17 Mueller W, Panse O, Brand S, Staubli A. In vivo study of the distribution, cartilage affinity and metabolism of glycosaminoglycan polysulfate (GAGPS). Z Rheumatol 1983; 42: 355-61.
    PubMedGoogle Scholar
  • 18 Lane DA, Michalski R, Van Ross ME, Kakkar VV. Comparison of heparin and a semi-synthetic heparin analogue, A73025. Br J Haematol 1977; 37: 239-45.
    CrossrefPubMedGoogle Scholar
  • 19 Thomas DP, Lane DA, Michalski R, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-2.
    PubMedGoogle Scholar
  • 20 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-40.
    CrossrefPubMedGoogle Scholar
  • 21 Schmitz-Huebner U, Asbeck F, van de Loo J. In vivo studies on the inhibition of coagulation by fractionated heparin and by heparin analogue: II: Effects of a heparin analogue. Thromb Haemost 1981; 46: 617-20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Bauer F, Schulz P, Reber G, Bouvier CA. Anticoagulant properties of three mucopolysaccharides used in rheumatology. Thromb Haemostas 1983; 50: 652-5.
    PubMedGoogle Scholar
  • 23 Haas S, Stemberger AW, Fritsche HM, Wendt P, Blumel G. Study of a dose dependent effect of the glycosaminoglycan polysulfate on various parameters of blood coagulation. Semin Thromb Hemost 1991; 17: 214-8.
    PubMedGoogle Scholar
  • 24 Duncan JR, Prasse KW. Veterinary laboratory medicine. Clinical pathology. 2nd ed. Ames, Iowa: Iowa State University Press; 1987: 73-86.
    Google Scholar
  • 25 Green RA. Activated coagulation time in monitoring heparinized dogs. Am J Vet Res 1980; 41: 1793-7.
    PubMedGoogle Scholar
  • 26 Hellebrekers LJ, Slappendel RJ, van den Brom WE. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am J Vet Res 1985; 46: 1460-2.
    PubMedGoogle Scholar
  • 27 Greene CE, Meriwether E. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Am J Vet Res 1982; 43: 1473-7.
    PubMedGoogle Scholar
  • 28 Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin Thromb He-most 1986; 12: 1-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Beale BS, Goring RL, Clemmons RM, Altman D. The effect of semi-synthetic polysul-fated glycosaminoglycan on the hemostatic mechanism in the dog. Abstract. Vet Surg 1990; 19: 57.
    PubMedGoogle Scholar
  • 30 Pion PD, Kittleson MD. Therapy for feline aortic thromboembolism. In: Kirk RW. (ed). Current Veterinary Therapy X. Small Animal Practice. Philadelphia: Saunders; 1989: 299-301.
    Google Scholar
  • 31 MacHarg MA, Becht JL. The pharmacology of heparin prophylaxis. J Am Vet Med Assoc 1983; 183: 129-30.
    PubMedGoogle Scholar
  • 32 Torngren S, Kettunen K, Lahtinen J, Koppenhagen K, Brucke P, Hartl P, Hutter O, Haller P, Lahnborg G, Forsskahl B. A randomized study of semisynthetic heparin analogue and heparin in prophylaxis of deep vein thrombosis. Br J Surg 1984; 71: 817-20.
    CrossrefPubMedGoogle Scholar
  • 33 Mahaffey EA, Moore JN. Erythrocyte agglutination associated with heparin treatment in three horses. J Am Vet Med Assoc 1986; 189: 1478-80.
    PubMedGoogle Scholar
  • 34 Moore JN, Mahaffey EA, Zboran M. Heparin-induced agglutination of erythrocytes in horses. Am J Vet Res 1978; 48: 68-71.
    PubMedGoogle Scholar
  • 35 Gerhards H. Low dose calcium heparin in horses: plasma heparin concentrations, effects on red blood cell mass and on coagulation variables. Equine Vet J 1991; 23: 37-43.
    CrossrefPubMedGoogle Scholar